One key factor that has developed increasing research interest is the role of a patient’s BMI, specifically those with obesity (BMI > 30 kg/m2), in the development of IBD.
C. Andrew Kistler, MD, PharmD
Andy authors Cancer Therapy Advisor's "In the Clinic" column. He is a gastroenterologist with interests in GI oncology, immunotherapy, the gut microbiome, and clinical pharmacology.